CoChat

Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Mycobacterium chelonae is a rare cause of chronic disseminated cutaneous infections in immunocompromised patients. Multidrug-resistant M. chelonae infections present a challenge for treatment, and prolonged antimicrobial courses lead to significant toxicities and further antimicrobial resistance. We report a case of refractory cutaneous disseminated M. chelonae infection in a patient with seronegative arthritis on immunotherapy with tofacitinib that was treated with combination antimicrobial, surgical, and single bacteriophage therapy with excellent clinical response. The patient developed neutralizing antibodies against the bacteriophage but continues to have stable improvement of disease with negative biopsies and no evidence of bacterial resistance to the phage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29689-4

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clinical course of M. chelonae infection. A Left upper extremity with multiple large erythematous, fluctuant to nodular lesions ultimately diagnosed as disseminated cutaneous Mycobacterium chelonae infection. B Images of the left upper extremity lesions prior to (Dec 2020) and following (August 2021) addition of bacteriophage therapy. C PET/CT prior to (March 2021) and following (August 2021) addition of bacteriophage therapy.
Fig. 1 Clinical course of M. chelonae infection. A Left upper extremity with multiple large erythematous, fluctuant to nodular lesions ultimately diagnosed as disseminated cutaneous Mycobacterium chelonae infection. B Images of the left upper extremity lesions prior to (Dec 2020) and following (August 2021) addition of bacteriophage therapy. C PET/CT prior to (March 2021) and following (August 2021) addition of bacteriophage therapy.CC BY · PubMed Central
Fig. 2 Treatment of M. chelonae infection. Timeline of antimicrobial and bacteriophage administration for M. chelonae infection from January 2020 to December 2021.
Fig. 2 Treatment of M. chelonae infection. Timeline of antimicrobial and bacteriophage administration for M. chelonae infection from January 2020 to December 2021.CC BY · PubMed Central
Fig. 3 Bacteriophages for therapy of M. chelonae. A Ten-fold serial dilutions of each phage (left) were spotted onto top agar overlays of M. smegmatis mc2155 and M. chelonae GD153. Phages: 1, BPs∆33HTH_HRM10; 2, BPs∆33HTH_HRMGD03; 3, Muddy; 4, Muddy_HRMGD04; 5, Itos; 6, Adephagia∆41∆43; 7, ZoeJ∆45; 8, Fionnbharth∆45∆47; 9, Elmo_HRMmc2155; 10, Isca_cpm; 11, Fred313cpm_∆33; 12, CrimD∆41-43; 13- BPs∆33HTH_HRM10_REM1; 14, Faith1∆38-40; 15, Faith1∆38-40_HRMGD69; 16, MissWhite; 17, MissWhite-D29_Hybrid1, 18, Maco6; 19, TM4; 20, Wildcat; 21, D29; and 22, D29_HRMGD40. B As for panel A but using M. abscessus lytically induced prophages plated on M. chelonae GD153 and control strain M. abscessus GD40. Phages: 1, phiGD20-1; 2, phiGD22-1; 3, phiGD23-1; 4, phiGD21-1; 5, phiGD34-2; 6, phiGD89-1; 7, phiGD57-1; 8, phiGD17-1; 9, phiGD24-3. C Killing of M. chelonae GD153 by Muddy following infection in liquid culture (moi, 10); -Muddy, no phage control. D Efficient killing of M. chelonae GD153 over ranges of bacterial and phage concentrations. All rows contain 10-fold serial dilutions of bacterial culture. Top row (–), no phage control; rows 2-9, 10-fold serial diltions, with 1010 PFU in row 2. E ELISA responses for anti-Muddy IgG antibodies in sera from 3 days, 17 days or 16 weeks after phage treatment initiation. Negative controls (ctrl) for uncoated wells are also shown. n = 2 technical replicates are shown. Data points are the average of two independent sets of serum dilutions and measurements, with error bars ± one standard deviation. F Half-maximal IgG titers derived from ELISA curve fits in panel D. Duplicate measurements are shown as points; bar height is the mean titer with error bars±one standard deviation. Source data for panels E and F are provided as a Source Data file. G To test for antibody neutralization, Muddy was incubated with either plasma (p) or serum (s) from 2 days, 3 days, 17 days or 16 weeks after the start of phage administration for 2 h (top) or 24 h (bottom) and then 10-fold serial dilutions were spotted onto top agar overlays of M. smegmatis mc2155. Plates were incubated at 37 °C for 48 h.
Fig. 3 Bacteriophages for therapy of M. chelonae. A Ten-fold serial dilutions of each phage (left) were spotted onto top agar overlays of M. smegmatis mc2155 and M. chelonae GD153. Phages: 1, BPs∆33HTH_HRM10; 2, BPs∆33HTH_HRMGD03; 3, Muddy; 4, Muddy_HRMGD04; 5, Itos; 6, Adephagia∆41∆43; 7, ZoeJ∆45; 8, Fionnbharth∆45∆47; 9, Elmo_HRMmc2155; 10, Isca_cpm; 11, Fred313cpm_∆33; 12, CrimD∆41-43; 13- BPs∆33HTH_HRM10_REM1; 14, Faith1∆38-40; 15, Faith1∆38-40_HRMGD69; 16, MissWhite; 17, MissWhite-D29_Hybrid1, 18, Maco6; 19, TM4; 20, Wildcat; 21, D29; and 22, D29_HRMGD40. B As for panel A but using M. abscessus lytically induced prophages plated on M. chelonae GD153 and control strain M. abscessus GD40. Phages: 1, phiGD20-1; 2, phiGD22-1; 3, phiGD23-1; 4, phiGD21-1; 5, phiGD34-2; 6, phiGD89-1; 7, phiGD57-1; 8, phiGD17-1; 9, phiGD24-3. C Killing of M. chelonae GD153 by Muddy following infection in liquid culture (moi, 10); -Muddy, no phage control. D Efficient killing of M. chelonae GD153 over ranges of bacterial and phage concentrations. All rows contain 10-fold serial dilutions of bacterial culture. Top row (–), no phage control; rows 2-9, 10-fold serial diltions, with 1010 PFU in row 2. E ELISA responses for anti-Muddy IgG antibodies in sera from 3 days, 17 days or 16 weeks after phage treatment initiation. Negative controls (ctrl) for uncoated wells are also shown. n = 2 technical replicates are shown. Data points are the average of two independent sets of serum dilutions and measurements, with error bars ± one standard deviation. F Half-maximal IgG titers derived from ELISA curve fits in panel D. Duplicate measurements are shown as points; bar height is the mean titer with error bars±one standard deviation. Source data for panels E and F are provided as a Source Data file. G To test for antibody neutralization, Muddy was incubated with either plasma (p) or serum (s) from 2 days, 3 days, 17 days or 16 weeks after the start of phage administration for 2 h (top) or 24 h (bottom) and then 10-fold serial dilutions were spotted onto top agar overlays of M. smegmatis mc2155. Plates were incubated at 37 °C for 48 h.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 139

Metadata

Authors
Little, J. S., Dedrick, R. M., Freeman, K. G., Cristinziano, M., Smith, B. E., Benson, C. A., Jhaveri, T. A., Baden, L. R., Solomon, D. A., & Hatfull, G. F.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Pittsburgh (US)
  • University of California San Diego (US)
Corresponding author
Little, Jessica S.
Venue
Nature Communications
Published
2022-05-03
Volume
13
Issue
1
Pages
2313-2313
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4225312054
Cited by
128
References
23
Citations by year
2026: 19 · 2025: 32 · 2024: 27 · 2023: 32 · 2022: 18
FWCI
19.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • U.S. Department of Health & Human Services | National Institutes of Health (GM131729)
  • Howard Hughes Medical Institute (GT12053)
  • Cystic Fibrosis Foundation (HATFUL19GO)
Topics
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
  • Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
  • Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
Keywords
Mycobacterium chelonae, phage therapy, multidrug-resistant mycobacteria, refractory infection, tofacitinib, immunotherapy, seronegative arthritis, immunocompromised patients, neutralizing antibodies, surgical debridement, combination antimicrobial therapy
MeSH terms
Anti-Bacterial Agents, Bacteriophages, Humans, Mycobacterium Infections, Nontuberculous, Mycobacterium chelonae, Skin Diseases, Bacterial, Clarithromycin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. https://app.cochat.ai/papers/10.1038/s41467-022-29689-4
The paper
Little, J. S., Dedrick, R. M., Freeman, K. G., Cristinziano, M., Smith, B. E., Benson, C. A., Jhaveri, T. A., Baden, L. R., Solomon, D. A., & Hatfull, G. F. (2022). Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nature Communications. https://doi.org/10.1038/s41467-022-29689-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.